Magava - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 630,612 | 447,129 | 517,103 | 688,719 | 1,140,392 | 438,330 | 100,260 | 157,640 |
| Profit before tax | - | - | - | - | 14,645 | - | - | - |
| Net profit | -22,243 | -30,785 | 4,622 | 20,387 | 13,940 | -74,055 | -69,804 | -90,730 |
| Equity | 27,348 | -3,436 | 1,186 | 21,365 | -14,447 | -88,501 | -158,305 | -249,035 |
| Liabilities | 31,477 | 33,152 | 470,392 | 579,652 | 943,667 | 744,694 | 799,732 | 814,765 |
| Non-current assets | 30,708 | 17,670 | 325,026 | 332,728 | 485,901 | 435,758 | 449,466 | 393,842 |
| Current assets | 28,099 | 11,943 | 137,369 | 266,756 | 439,793 | 218,457 | 184,019 | 168,462 |
| Total assets | 58,807 | 29,613 | 462,395 | 599,484 | 925,694 | 654,215 | 633,485 | 562,304 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 118,727 | 15,730 | 52,931 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +27.2% | -29.1% | +15.6% | +33.2% | +65.6% | -61.6% | -77.1% | +57.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -37.8% | -104.0% | 1.0% | 3.4% | 1.5% | -11.3% | -11.0% | -16.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -81.3% | - | 389.7% | 95.4% | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -3.5% | -6.9% | 0.9% | 3.0% | 1.2% | -16.9% | -69.6% | -57.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 1.3% | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.2 | - | 396.6 | 27.1 | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 204,525 | 121,943 | 344,735 | 688,719 | 1,140,392 | 438,330 | 100,260 | 157,640 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Magava - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-04-16 | 2024-04-18 | 319.42 |
| 2023-02-17 | 2023-02-20 | 308.84 |
Magava - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Magava, UAB (code 303085610) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, revenue was €157.6K and net loss €90.7K, corresponding to a negative profit margin of 57.6%. Revenue increased by 57.2% year on year from 2024, but it remained well below the €438.3K reported in 2023, so the three-year trend still shows a sharp overall contraction. Losses widened in 2025 compared with 2024, despite the higher turnover. At the balance sheet level, total assets declined to €562.3K from €633.5K in 2024 and €654.2K in 2023, while liabilities rose to €814.8K. Equity remained negative and decreased further to €249.0K below zero, indicating continued financial pressure. Long-term assets stood at €393.8K and short-term assets at €168.5K. Asset turnover was 0.28x, showing limited use of assets to generate revenue. Revenue per employee was €157.6K, while profit per employee was negative due to the loss in 2025.